AJOVY is indicated for the preventive treatment of migraine in adults.

You can also browse the topics below to find what you are looking for.

AJOVY SELECTIVELY TARGETS THE LIGAND1

IgG TYPE AND TARGET OF AJOVY vs COMPETITORS

  AJOVY® (fremanezumab-vfrm)1 Aimovig®
(erenumab-aooe)2		 Emgality®
(galcanezumab-gnlm)3		 Nurtec®
(rimegepant)4		 Qulipta®
(atogepant)5
Target ligand receptor ligand receptor receptor
IgG isotype IgG2Δa IgG2 IgG4    

This information should not be construed to imply any difference in safety, efficacy, or other clinical outcome.

AJOVY®
(fremanezumab-vfrm)1		 ligand 
Target		 IgG2ΔaIgG
isotype
Aimovig® (erenumab-aooe)2
receptor
IgG2
Emgality® (galcanezumab-gnlm)3
ligand
IgG4
Nurtec® (rimegepant)4
receptor
 
Qulipta® (atogepant)5
receptor
 

This information should not be construed to imply any difference in safety, efficacy, or other clinical outcome.

AJOVY involves exclusive binding to the CGRP ligand and does not exhibit off–site binding to related calcitonin family members6

AJOVY was specifically bioengineered to reduce unwanted activation of the immune system, which is achieved by its IgG2Δa antibody type.7

In clinical trials:

  • The most common adverse reactions in clinical trials (≥5% and greater than placebo) were injection-site reactions1
  • <1% of patients experienced constipation vs <1% with placebo7
  • <1% of patients experienced hypertension vs <1% with placebo7

Aimovig® is a registered trademark owned or licensed by Amgen Inc. Emgality® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

Nurtec® is a registered trademark owned or licensed by Pfizer Inc. Qulipta® is a registered trademark owned or licensed by AbbVie.

NOW is the time for AJOVY
​

References: 1. AJOVY® (fremanezumab-vfrm) injection. Current Prescribing Information. North Wales, PA: Teva Pharmaceuticals USA, Inc. 2. Aimovig® (erenumab-aooe) injection. Prescribing Information. Thousand Oaks, CA: Amgen Inc. 3. Emgality® (galcanezumab-gnlm) injection. Prescribing Information. Indianapolis, IN. Lilly USA, LLC. 4. Nurtec® ODT (rimegepant) orally disintegrating tablets. Prescribing Information. New York, NY. Pfizer Inc. 5. QULIPTA® (atogepant) tablets. Prescribing Information. North Chicago, IL. AbbVie Inc. 6. Bhakta M, Vuong T, Taura T, Wilson DS, Stratton JR, Mackenzie KD. Migraine therapeutics differentially modulate the CGRP pathway. Cephalalgia. 2021;41(5):499-514. 7. Data on file. Parsippany, NJ: Teva Pharmaceuticals USA, Inc.